Advertisement

Congenital Adrenal Hyperplasia Owing to 17α-Hydroxylase/17,20 Lyase and P450 Oxidoreductase Deficiencies

  • Christa E. FlückEmail author
Conference paper
  • 1.2k Downloads
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 707)

Abstract

Congenital adrenal hyperplasia (CAH) due to genetic mutations in the genes for CYP17A1 (MIM 609300) and CYP OR (MIM 124015) are rare and may cause disordered sexual development (DSD).

Keywords

Congenital Adrenal Hyperplasia Prenatal Androgen Craniosynostosis Syndrome CYP17A1 Mutation P450 Oxidoreductase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Biglieri EG, Herron MA & Brust N 1966 17-Hydroxylation deficiency in man. J Clin Invest 45 1946–1954.PubMedCrossRefGoogle Scholar
  2. 2.
    New MI 1970 Male pseudohermaphroditism due to 17 alpha-hydroxylase deficiency. J Clin Invest 49 1930–1941.PubMedCrossRefGoogle Scholar
  3. 3.
    Kagimoto M, Winter JS, Kagimoto K, Simpson ER & Waterman MR 1988 Structural characterization of normal and mutant human steroid 17 alpha-hydroxylase genes: molecular basis of one example of combined 17 alpha-hydroxylase/17,20 lyase deficiency. Mol Endocrinol 2 564–570.PubMedCrossRefGoogle Scholar
  4. 4.
    Costa-Santos M, Kater CE & Auchus RJ 2004 Two prevalent CYP17 mutations and genotype-phenotype correlations in 24 Brazilian patients with 17-hydroxylase deficiency. J Clin Endocrinol Metab 89 49–60.PubMedCrossRefGoogle Scholar
  5. 5.
    Geller DH, Auchus RJ, Mendonca BB & Miller WL 1997 The genetic and functional basis of isolated 17,20-lyase deficiency. Nat Genet 17 201–205.PubMedCrossRefGoogle Scholar
  6. 6.
    Sherbet DP, Tiosano D, Kwist KM, Hochberg Z & Auchus RJ 2003 CYP17 mutation E305G causes isolated 17,20-lyase deficiency by selectively altering substrate binding. J Biol Chem 278 48563–48569.PubMedCrossRefGoogle Scholar
  7. 7.
    Van Den Akker EL, Koper JW, Boehmer AL, Themmen AP, Verhoef-Post M, Timmerman MA, Otten BJ, Drop SL & De Jong FH 2002 Differential inhibition of 17a-hydroxylase and 17,20-lyase activities by three novel missense CYP17 mutations identified in patients with P450c17 deficiency. J Clin Endocrinol Metab 87 5714–5721.CrossRefGoogle Scholar
  8. 8.
    Geller DH, Auchus RJ & Miller WL 1999 P450c17 mutations R347H and R358Q selectively disrupt 17,20-lyase activity by disrupting interactions with P450 oxidoreductase and cytochrome b5. Mol Endocrinol 13 167–175.PubMedCrossRefGoogle Scholar
  9. 9.
    Peterson RE, Imperato-McGinley J, Gautier T & Shackleton CHL 1985 Male pseudohermaphroditism due to multiple defects in steroid-biosynthetic microsomal mixed-function oxidases. A new variant of congenital adrenal hyperplasia. N Engl J Med 313 1182–1191.PubMedCrossRefGoogle Scholar
  10. 10.
    Reardon W, Smith A, Honour JW, Hindmarsh P, Das D, Rumsby G, Nelson I, Malcolm S, Ades L, Sillence D, et al. 2000 Evidence for digenic inheritance in some cases of Antley-Bixler syndrome? J Med Genet 37 26–32.PubMedCrossRefGoogle Scholar
  11. 11.
    Fluck CE, Pandey AV, Huang N, Agrawal V & Miller WL 2008 P450 oxidoreductase deficiency – a new form of congenital adrenal hyperplasia. Endocr Dev 13 67–81.PubMedCrossRefGoogle Scholar
  12. 12.
    Arlt W, Walker EA, Draper N, Ivison HE, Ride JP, Hammer F, Chalder SM, Borucka-Mankiewicz M, Hauffa BP, Malunowicz EM, et al. 2004 Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. Lancet 363 2128–2135.PubMedCrossRefGoogle Scholar
  13. 13.
    Flück CE, Tajima T, Pandey AV, Arlt W, Okuhara K, Verge CF, Jabs EW, Mendonca BB, Fujieda K & Miller WL 2004 Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat Genet 36 228–230.PubMedCrossRefGoogle Scholar
  14. 14.
    Fukami M, Nishimura G, Homma K, Nagai T, Hanaki K, Uematsu A, Ishii T, Numakura C, Sawada H, Nakacho M, et al. 2009 Cytochrome P450 oxidoreductase deficiency: identification and characterization of biallelic mutations and genotype-phenotype correlations in 35 Japanese patients. J Clin Endocrinol Metab 94 1723–1731.PubMedCrossRefGoogle Scholar
  15. 15.
    Huang N, Pandey AV, Agrawal V, Reardon W, Lapunzina PD, Mowat D, Jabs EW, Van Vliet G, Sack J, Flück CE, et al. 2005 Diversity and function of mutations in P450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. Am J Hum Genet 76 729–749.PubMedCrossRefGoogle Scholar
  16. 16.
    Pandey AV, Kempna P, Hofer G, Mullis PE & Fluck CE 2007 Modulation of human CYP19A1 activity by mutant NADPH P450 oxidoreductase. Mol Endocrinol 21 2579–2595.PubMedCrossRefGoogle Scholar
  17. 17.
    Dhir V, Ivison HE, Krone N, Shackleton CHL, Doherty AJ, Stewart PM & Arlt W 2007 Differential inhibition of CYP17A1 and CYP21A2 activities by the P450 oxidoreductase mutant A287P. Mol Endocrinol 21 1958–1968.PubMedCrossRefGoogle Scholar
  18. 18.
    Huang N, Agrawal V, Giacomini KM & Miller WL 2008 Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc Natl Acad Sci USA 105 1733–1738.PubMedCrossRefGoogle Scholar
  19. 19.
    Agrawal V, Huang N & Miller WL 2008 Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19. Pharmacogenet Genomics 18 569–576.PubMedCrossRefGoogle Scholar
  20. 20.
    Nicolo C, Fluck CE, Mullis PE & Pandey AV 2010 Restoration of mutant cytochrome P450 reductase activity by external flavin. Mol Cell Endocrinol 321 245–252.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Pediatric Endocrinology and DiabetologyUniversity Children’s Hospital, University of BernBernSwitzerland

Personalised recommendations